JP2011530535A - グリコシド化合物およびその医薬組成物 - Google Patents

グリコシド化合物およびその医薬組成物 Download PDF

Info

Publication number
JP2011530535A
JP2011530535A JP2011522277A JP2011522277A JP2011530535A JP 2011530535 A JP2011530535 A JP 2011530535A JP 2011522277 A JP2011522277 A JP 2011522277A JP 2011522277 A JP2011522277 A JP 2011522277A JP 2011530535 A JP2011530535 A JP 2011530535A
Authority
JP
Japan
Prior art keywords
cancer
disease
mmol
compound
vasculitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011522277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011530535A5 (enExample
Inventor
チャールズ アール． ハッチンソン，
モハメッド エス． シェカーニ，
ジェイムズ アール． プルデント，
Original Assignee
セントローズ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントローズ， エルエルシー filed Critical セントローズ， エルエルシー
Publication of JP2011530535A publication Critical patent/JP2011530535A/ja
Publication of JP2011530535A5 publication Critical patent/JP2011530535A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • C07J19/005—Glycosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2011522277A 2008-08-07 2009-08-07 グリコシド化合物およびその医薬組成物 Pending JP2011530535A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8701008P 2008-08-07 2008-08-07
US61/087,010 2008-08-07
PCT/US2009/053159 WO2010017480A1 (en) 2008-08-07 2009-08-07 Glycoside compounds and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
JP2011530535A true JP2011530535A (ja) 2011-12-22
JP2011530535A5 JP2011530535A5 (enExample) 2013-05-02

Family

ID=41663995

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011522277A Pending JP2011530535A (ja) 2008-08-07 2009-08-07 グリコシド化合物およびその医薬組成物

Country Status (4)

Country Link
US (2) US8361973B2 (enExample)
EP (1) EP2320729B1 (enExample)
JP (1) JP2011530535A (enExample)
WO (1) WO2010017480A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017088547A (ja) * 2015-11-11 2017-05-25 花王株式会社 毛成長抑制剤

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010017480A1 (en) 2008-08-07 2010-02-11 Centrose, Llc Glycoside compounds and pharmaceutical compositions thereof
AU2010292172A1 (en) * 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
ES2654584T3 (es) 2010-01-15 2018-02-14 Suzhou Neupharma Co., Ltd Ciertas entidades químicas, composiciones y métodos
EP3453714B1 (en) 2011-02-02 2020-11-04 Suzhou Neupharma Co., Ltd Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof
US20140079722A1 (en) * 2011-03-09 2014-03-20 Centrose, Llc Extracellular targeted drug conjugates
EP3453713B1 (en) * 2012-04-29 2021-09-08 Neupharma, Inc. Bufadienolide compounds substituted in position 3 by an amine group for use in the treatment of cancer
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
US20190008983A1 (en) 2015-07-31 2019-01-10 James R. Prudent Extracellular drug conjugates targeting cd20
GB2607692B (en) 2019-08-23 2023-08-02 Imagination Tech Ltd Random accessible image data compression
WO2021054978A1 (en) * 2019-09-20 2021-03-25 Pollard Bette Silver Cardiac cardenolides to reduce fibrosis and enhance epithelial differentiation

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4976858A (enExample) * 1972-11-04 1974-07-24
JPS63502189A (ja) * 1986-01-09 1988-08-25 フアルミタリア　カルロ　エルバ　ソシエテ　パル　アクチオン ノル−コラン酸誘導体、それらの製造方法、それらの用途及びそれらを含有する治療用組成物
JPH0899894A (ja) * 1994-06-10 1996-04-16 Akira Matsumori 炎症性サイトカイン分泌抑制剤
WO2002014343A1 (en) * 2000-08-17 2002-02-21 Terness, Peter Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents
JP2002536415A (ja) * 1999-02-12 2002-10-29 セルパス インコーポレイテッド 抗腫瘍療法
WO2004087121A2 (en) * 2003-03-28 2004-10-14 Azaya Therapeutics, Inc. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
JP2007008879A (ja) * 2005-06-30 2007-01-18 Yanbaru Green Health:Kk 抗腫瘍剤及びこれを含有する食品
WO2007081835A2 (en) * 2006-01-09 2007-07-19 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
JP2008504284A (ja) * 2004-06-24 2008-02-14 ウィスコンシン アルムニ リサーチ ファンデイション 新生糖ランダム化及びジギトキシン類似体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987031A (en) 1970-12-23 1976-10-19 Boehringer Ingelheim Gmbh Acyl derivatives of proscillaridin a
DE2319874C2 (de) * 1973-04-19 1983-06-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Derivate des Digitoxigenin-α-L-arabinosids, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
NZ199543A (en) * 1981-01-23 1985-04-30 Wellcome Found Inclusion complexes of cyclodextrins and cardiac clycosides;pharmaceutical formulations
US5280113A (en) * 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5668272A (en) * 1995-06-30 1997-09-16 National Research Council Of Canada Method for producing synthetic N-linked glycoconjugates
US6180612B1 (en) * 1997-10-31 2001-01-30 The University Of Virginia Patent Foundation Methods and compositions for targeting DNA metabolic processes using aminoglycoside derivatives
US20030031677A1 (en) 2001-06-25 2003-02-13 Drug Innovation & Design, Incorporated Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
US7402325B2 (en) * 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
JP5385135B2 (ja) 2006-07-03 2014-01-08 チャールズ デイビッド アデア， 細胞接着分子の発現を調節するための組成物
WO2008121797A1 (en) 2007-03-28 2008-10-09 Novartis Ag Fxdy5 modulators for treating, diagnosing, and detecting cancer
WO2010017480A1 (en) 2008-08-07 2010-02-11 Centrose, Llc Glycoside compounds and pharmaceutical compositions thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4976858A (enExample) * 1972-11-04 1974-07-24
JPS63502189A (ja) * 1986-01-09 1988-08-25 フアルミタリア　カルロ　エルバ　ソシエテ　パル　アクチオン ノル−コラン酸誘導体、それらの製造方法、それらの用途及びそれらを含有する治療用組成物
JPH0899894A (ja) * 1994-06-10 1996-04-16 Akira Matsumori 炎症性サイトカイン分泌抑制剤
JP2002536415A (ja) * 1999-02-12 2002-10-29 セルパス インコーポレイテッド 抗腫瘍療法
WO2002014343A1 (en) * 2000-08-17 2002-02-21 Terness, Peter Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents
WO2004087121A2 (en) * 2003-03-28 2004-10-14 Azaya Therapeutics, Inc. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
JP2008504284A (ja) * 2004-06-24 2008-02-14 ウィスコンシン アルムニ リサーチ ファンデイション 新生糖ランダム化及びジギトキシン類似体
JP2007008879A (ja) * 2005-06-30 2007-01-18 Yanbaru Green Health:Kk 抗腫瘍剤及びこれを含有する食品
WO2007081835A2 (en) * 2006-01-09 2007-07-19 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN6013049581; Ｐｈｙｔｏｃｈｅｍｉｓｔｒｙ ３７（５）, 1994, １４２１-１４２３ *
JPN6013049582; Ｐｈｙｔｏｃｈｅｍｉｓｔｒｙ ４１（１）, 1996, １２５-１２７ *
JPN6014045750; Ｊｏｕｒｎａｌ　ｏｆ　Ｃａｒｂｏｈｙｄｒａｔｅ　Ｃｈｅｍｉｓｔｒｙ １７（１）, 1998, ７５-９８ *
JPN6014045753; Ｑｕａｎｔｉｔａｔｉｖｅ　Ｓｔｒｕｃｔｕｒｅ-Ａｃｔｉｖｉｔｙ　Ｒｅｌａｔｉｏｎｓｈｉｐｓ ７（３）, 1988, １６０-１６５ *
JPN6014045754; Ｊｏｕｒｎａｌ　ｏｆ　Ｎａｔｕｒａｌ　Ｐｒｏｄｕｃｔｓ ７０（９）, 2007, １４２９-１４３３ *
JPN6014045757; Ｊｏｕｒｎａｌ　ｏｆ　Ｎａｔｕｒａｌ　Ｐｒｏｄｕｃｔｓ ４２（３）, 1979, ２９３-２９８ *
JPN7013003698; Ｐｒｏｃｅｅｄｉｎｇｓ　ｏｆ　ｔｈｅ　Ｎａｔｉｏｎａｌ　Ａｃａｄｅｍｙ　ｏｆ　Ｓｃｉｅｎｃｅｓ　ｏｆ　ｔｈｅ　Ｕｎｉｔｅｄ　Ｓｔａｔｅｓ　ｏｆ　Ａｍｅｒｉｃａ １０２（３５）, 2005, １２３０５-１２３１０ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017088547A (ja) * 2015-11-11 2017-05-25 花王株式会社 毛成長抑制剤

Also Published As

Publication number Publication date
US20130178431A1 (en) 2013-07-11
US8361973B2 (en) 2013-01-29
EP2320729B1 (en) 2015-04-22
EP2320729A4 (en) 2013-04-03
US20110319350A1 (en) 2011-12-29
WO2010017480A1 (en) 2010-02-11
EP2320729A1 (en) 2011-05-18
US8703723B2 (en) 2014-04-22

Similar Documents

Publication Publication Date Title
US8361973B2 (en) Glycoside compounds and pharmaceutical compositions thereof
KR101646960B1 (ko) 신규한 황산화된 올리고사카라이드 유도체
AU2013249429B2 (en) Targeted therapeutics
EP1249450B1 (en) Benzimidazole derivatives as human chymase inhibitors
AU2015224576A1 (en) Targeted therapeutics
EP2900678B1 (en) Multimeric mannosides, a process for preparing the same and their uses as a drug
CN103002890A (zh) 靶向癌症干细胞的新的化合物和组合物
CN103025159A (zh) 靶向癌症干细胞的新方法
CA3114055A1 (en) Prodrug of galactoside inhibitors of galectins
KR20200108303A (ko) 갈렉틴의 신규 갈락토시드 억제제
US20230134986A1 (en) Glucose triptolide conjugates and uses thereof
ES2300877T3 (es) Derivados de esteroides glucosilados con actividad antimigratoria.
AU2011291709B2 (en) Crystal form of 4-isopropylphenyl glucitol compound and process for production thereof
CN101296694A (zh) 药物镓组合物和方法
CN101402667A (zh) 糖基化修饰的一氧化氮供体型齐墩果酸类化合物、其制备方法及用途
JPWO2012023600A1 (ja) ４−イソプロピル−６−メトキシフェニルグルシトール化合物
EP1572715B1 (en) Steroid compounds with anti-tumor activity
JP2020507591A (ja) 抗がん活性を有するステロイドサポニン
CN101885726B (zh) 化合物结构及制备方法与用途
CN100516083C (zh) 具有抗迁移活性的糖基化类固醇衍生物
EP4474386A1 (en) Anthracyclines
WO2010102673A1 (en) Hellebrin and hellebrigenin derivatives
HK1085744B (en) Steroid compounds with anti-tumor activity
JP2006511483A (ja) ２’’オキソ−ボルウスカリンおよびその誘導体
HK1183025B (en) Crystal form of 4-isopropylphenyl glucitol compound and process for production thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140303

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150422